Publication

For many neglected diseases, the drug and vaccine candidates now in the pipeline are the first new therapies and prevention tools in a generation; for others, they are simply the first ever. Effective remedies have been few because of low investment, but with a surge in funding in the past decade, dozens of candidate drugs and vaccines are now in the pipeline. Before these products can reach the people who need them, they must be tested in large-scale clinical trials that are expensive, time-consuming, and risky.